Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction

医学 沙库比林、缬沙坦 缬沙坦 射血分数 心脏病学 沙库比林 心力衰竭 内科学 血压
作者
Alberto Foà,Muthiah Vaduganathan,Brian Claggett,Maria Pabón,Henri Lu,Marc A. Pfeffer,Milton Packer,Orly Vardeny,Jean L. Rouleau,Martin Lefkowitz,Robert J. Mentz,Pardeep S. Jhund,Akshay S. Desai,John J.V. McMurray,Scott D. Solomon
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:83 (18): 1731-1739 被引量:12
标识
DOI:10.1016/j.jacc.2024.02.035
摘要

Hypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in HFmrEF and HFpEF. We investigated predictors of treatment-associated hypotension, clinical outcomes after hypotension, and the relationship between LVEF and incidence of hypotension in the PARAGON-HF trial. PARAGON-HF randomized patients with chronic HF (≥45%) to sacubitril/valsartan or valsartan. Following randomization, hypotension was defined as investigator-reported hypotension with a SBP <100 mmHg. Predictors of hypotension were assessed using multivariable Cox models. Associations between hypotension and clinical outcomes were evaluated in time-updated Cox models. The relationship between treatment, LVEF, and incident rates of hypotension and clinical outcomes was estimated using Poisson regression models. Of 4,796 patients in PARAGON-HF, 637 (13%) experienced hypotension, more frequently in the sacubitril/valsartan arm (p<0.001). Following documented hypotension, patients had higher risk of CV death and total HF hospitalizations (adjusted RR 1.63; CI 1.27-2.09; p<0.001) and all-cause death (adjusted HR 1.62; CI 1.28-2.05; p<0.001). LVEF modified the association between sacubitril/valsartan and risk of hypotension (Pinteraction=0.019) such that patients with LVEF≥60% experienced substantially higher treatment-related risks of hypotension. In PARAGON-HF, a higher LVEF was associated with an increased risk of hypotension in patients treated with sacubitril/valsartan compared with valsartan. Since these subjects are also less likely to derive clinical benefit from sacubitril/valsartan, our data reinforce that the benefit/risk ratio favors the use of sacubitril/valsartan in patients with LVEF below normal, but not at higher LVEF.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助动生电动势采纳,获得10
刚刚
陈cc完成签到,获得积分20
刚刚
小黄鸭完成签到,获得积分10
1秒前
浩天完成签到,获得积分10
1秒前
暴走诺亚发布了新的文献求助30
1秒前
李雪蒙发布了新的文献求助10
3秒前
Jasper应助合适的灵枫采纳,获得10
3秒前
天天快乐应助chen采纳,获得10
3秒前
4秒前
4秒前
爆米花应助Gesj采纳,获得10
4秒前
5秒前
5秒前
记忆缺失发布了新的文献求助10
5秒前
7秒前
7秒前
汉堡包应助smile采纳,获得10
7秒前
8秒前
苻莞发布了新的文献求助10
8秒前
lydiaabc发布了新的文献求助10
9秒前
勤劳的音响完成签到,获得积分10
9秒前
浩气长存完成签到 ,获得积分10
9秒前
9秒前
蓝灵完成签到,获得积分10
9秒前
zsk1122完成签到,获得积分10
9秒前
455完成签到,获得积分10
10秒前
10秒前
哇owao发布了新的文献求助10
10秒前
西门凡双完成签到,获得积分10
10秒前
暴走诺亚完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
魔真人关注了科研通微信公众号
11秒前
李健应助孟庆磊采纳,获得10
11秒前
11秒前
wefs完成签到,获得积分10
11秒前
12秒前
蓦然回首完成签到,获得积分10
12秒前
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969222
求助须知:如何正确求助?哪些是违规求助? 3514124
关于积分的说明 11171948
捐赠科研通 3249361
什么是DOI,文献DOI怎么找? 1794799
邀请新用户注册赠送积分活动 875431
科研通“疑难数据库(出版商)”最低求助积分说明 804779